Vivos Therapeutics, Inc. (VVOS): Nasdaq/NYSE listing notice — Vivos Therapeutics receives Nasdaq deficiency notice for bid price below $1.00 for 30 consecutive days

Vivos Therapeutics, Inc.

Received Nasdaq staff deficiency notice on March 24, 2023.
Closing bid price below $1.00 for 30 consecutive business days (Feb 9 to Mar 23, 2023).
Given 180-day compliance period until September 20, 2023 to regain compliance by closing at $1.00+ for 10 consecutive business days.
If not compliant, may be eligible for additional 180-day grace period if meets other listing standards.
Management intends to cure deficiency and continue listing on Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

March 24, 2023, Vivos Therapeutics, Inc. (the “Company”) received a staff deficiency notice from The Nasdaq Stock Market (“Nasdaq”) indicating that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days (February 9, 2023 through March 23, 2023), the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Rule 5550(a)(2) of the Nasdaq Listing Rules. Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Ma

View on SEC.gov

Browse all listing & compliance notices →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-009006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.